321-98-2

Basic information

• Product Name: (+)EPHEDRINE HEMIHYDRATE
• Synonyms: (+)-(1s,2r)-ephedrine;(1s,2r)-(+)-ephedrine;(1s,2r)-ephedrine;alpha-(1-(methylamino)ethyl)-,(s-(r*,s*))-benzenemethano;alpha-[1-(methylamino)ethyl]-,[s-(theta,s)]-benzenemethano;d-ephedrine;(1S,2R)-(+)-ephedrine, anhydre;2-alpha-(1-methylaminoethyl)benzylic alcohol
• CAS NO: 321-98-2
• Molecular Formula: C₁₀H₁₅NO
• Molecular Weight: 165.2322
• EINECS: 206-293-3
• Mol File: 321-98-2.mol
• Article Data: 22

Chemical Properties

• Melting Point: 40°C
• Boiling Point: 293.09°C (rough estimate)
• Flash Point: 85.6°C
• Appearance: /
• Density: 1.0203 (rough estimate)
• Vapor Pressure: 0.00865mmHg at 25°C
• Refractive Index: 1.4820 (estimate)
• PKA: 10.139(at 10℃)
• CAS DataBase Reference: (+)EPHEDRINE HEMIHYDRATE(CAS DataBase Reference)
• NIST Chemistry Reference: (+)EPHEDRINE HEMIHYDRATE(321-98-2)
• EPA Substance Registry System: (+)EPHEDRINE HEMIHYDRATE(321-98-2)

Safety Data

• Hazardous Substances Data: 321-98-2(Hazardous Substances Data)

Usage

General Description

The pharmacological activity of(1R,2S)-D-(-)-ephedrine resembles that of E. The drug actson both α- and β-receptors. Its ability to activate β-receptorsprobably accounted for its earlier use in asthma. It is theclassic example of a sympathomimetic with a mixed mechanismof action.

InChI:InChI=1/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10-/m1/s1

Upstream product

• 107-10-8 propylamine 
• 2799-16-8 (2R)-hydroxypropylamine 
• 299-42-3 ephedrine 
• 124-41-4 sodium methylate 
• 134-71-4 rac-ephedrine hydrochloride 
• 67-56-1 methanol 
• 4962-45-2 (1SR,2RS)-2-bromo-1-phenyl-1-propanol 
• 74-89-5 methylamine 
• 64-17-5 ethanol 
• 579-07-7 1-Phenylpropane-1,2-dione 
• 56-23-5 tetrachloromethane 
• 105-40-8 Ethyl N-methylcarbamate 
• 7726-95-6 bromine 
• 93982-06-0 (1S,2R)-(+)-ephedrinium (R)-(-)-mandelate 

Downstream Products

• 101288-61-3 (+/-)-3,4r-dimethyl-5t-phenyl-2ξ-[2]pyridyl-oxazolidine 
• 6317-31-3 trans-3,4-dimethyl-5-phenyloxazolidin-2-one 
• 90-86-8 D-erythro-2-(methyl-trans-cinnamyl-amino)-1-phenyl-propanol-⁽¹⁾ 
• 113750-46-2 (+/-)-3,4r-dimethyl-2ξ-octyl-5t-phenyl-oxazolidine 
• 2007-94-5 3,4r-dimethyl-5t-phenyl-oxazolidin-2-ylideneamine 
• 101778-30-7 (+/-)-2ξ-heptyl-3,4r-dimethyl-5t-phenyl-oxazolidine 
• 90-81-3 ephedrine 
• 321-97-1 (1R,2R)-pseudoephedrine 
• 42511-08-0 (1S,2R)-1-cyclohexyl-2-methylamino-propan-1-ol 
• 42510-95-2 N-((1RS,2RS)-2-hydroxy-1-methyl-2-phenyl-ethyl)-N-methyl-urea 
• 5650-44-2 methcathinone 
• 42511-08-0 (+/-)-hexahydro-pseudoephedrine 
• 25394-33-6 ((1RS,2SR)-2-chloro-1-methyl-2-phenyl-ethyl)-methyl-amine 
• 6402-25-1 (1RS:2RS)-2-methylamino-1-(4-amino-phenyl)-propanol-⁽¹⁾ 

Relevant articles and documents

Evaluation of the Edman degradation product of vancomycin bonded to core-shell particles as a new HPLC chiral stationary phase

A modified macrocyclic glycopeptide-based chiral stationary phase (CSP), prepared via Edman degradation of vancomycin, was evaluated as a chiral selector for the first time. Its applicability was compared with other macrocyclic glycopeptide-based CSPs: TeicoShell and VancoShell. In addition, another modified macrocyclic glycopeptide-based CSP, NicoShell, was further examined. Initial evaluation was focused on the complementary behavior with these glycopeptides. A screening procedure was used based on previous work for the enantiomeric separation of 50 chiral compounds including amino acids, pesticides, stimulants, and a variety of pharmaceuticals. Fast and efficient chiral separations resulted by using superficially porous (core-shell) particle supports. Overall, the vancomycin Edman degradation product (EDP) resembled TeicoShell with high enantioselectivity for acidic compounds in the polar ionic mode. The simultaneous enantiomeric separation of 5 racemic profens using liquid chromatography-mass spectrometry with EDP was performed in approximately 3?minutes. Other highlights include simultaneous liquid chromatography separations of rac-amphetamine and rac-methamphetamine with VancoShell, rac-pseudoephedrine and rac-ephedrine with NicoShell, and rac-dichlorprop and rac-haloxyfop with TeicoShell.

Diastereoselective hydrogenation of α,β-unsaturated but-2-enamides to access the chiral 3-(p-tolyl) butanoic acids

An alternative methodology for the synthesis of chiral 3-(p-tolyl) butanoic acids is presented. This was accomplished through the diastereoselective hydrogenation reaction of different chiral N-3-(p-tolyl) but-2-enamides, using Pd/C in EtOH, to produce the corresponding chiral N-3-(p-tolyl) butanamides with high chemical yields and moderate diastereomeric ratios. Removal of the chiral auxiliary from N-3-(p-tolyl) butanamides gave the respective enantiomerically pure acids.

Synthesis of three novel fluorine-18 labeled analogues of l -deprenyl for Positron Emission Tomography (PET) studies of Monoamine Oxidase B (MAO-B)

The aim in this project was to synthesize and to study fluorine-18 labeled analogues of l-deprenyl which bind selectively to the enzyme monoamine oxidase B (MAO-B). Three fluorinated l-deprenyl analogues have been generated in multistep organic syntheses. The most promising fluorine-18 compound N-[(2S)-1-[18F]fluoro-3-phenylpropan-2-yl]-N-methylprop-2-yn-1-amine (4c) was synthesized by a one-step fluorine-18 nucleophilic substitution reaction. Autoradiography on human brain tissue sections demonstrated specific binding for compound 4c to brain regions known to have a high content of MAO-B. In addition, the corresponding nonradioactive fluorine-19 compound (13) inhibited recombinant human MAO-B with an IC50 of 170.5 ±29 nM but did not inhibit recombinant human MAO-A (IC50 > 2000 nM), demonstrating its specificity. Biodistribution of 4c in mice showed high initial brain uptake leveling at 5.2 ±0.04%ID/g after 2 min post injection. In conclusion, compound 4c is a specific inhibitor of MAO-B with high initial brain uptake in mice and is, therefore, a candidate for further investigation in PET.